Medical information Clinical review pending

Genetic Testing

RAG2 Gene Combined Cellular and Humoral Immune Defects with Granulomas Genetic Test

Genetic test using Next Generation Sequencing (NGS) to analyze the RAG2 gene for mutations associated with combined cellular and humoral immune deficiencies and granulomas. Helps diagnose specific immune system disorders.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Blood sample (EDTA tube), extracted DNA, or dried blood spot on FTA card.
Results: Approximately 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation: No specific patient preparation is required. A clinical history and pedigree chart (if available) are helpful for interpretation. Confirm with the laboratory before booking.

Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the RAG2 Gene Combined Cellular and Humoral Immune Defects with Granulomas Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Recurrent or unusual infections
✓Family history of primary immunodeficiency
✓Presence of granulomas without clear cause
✓Symptoms suggestive of combined immunodeficiency
✓Failure to thrive in infancy
✓Screening in individuals with suspected immune disorders

In plain language

What this test helps you understand

This test helps identify specific genetic mutations in the RAG2 gene associated with severe combined immunodeficiency (SCID) and other immune disorders characterized by combined cellular and humoral immune defects, often accompanied by granulomas. Early diagnosis can guide appropriate medical management and treatment strategies.

The RAG2 Gene Combined Cellular and Humoral Immune Defects with Granulomas NGS Genetic DNA Test is a diagnostic tool used to identify genetic mutations affecting the immune system. This test utilizes Next Generation Sequencing (NGS) technology for a comprehensive analysis of the RAG2 gene, which plays a crucial role in immune function. Understanding these genetic factors can lead to early intervention and better management of related health conditions. This test specifically measures defects in the RAG2 gene, which are linked to combined cellular and humoral immune deficiencies. By analyzing genetic material, the test detects mutations that may cause serious immune disorders, including granulomas. Results provide insights into the presence of mutations, and genetic counseling is available to help interpret the findings and understand their implications.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationNo specific patient preparation is required. A clinical history and pedigree chart (if available) are helpful for interpretation. Confirm with the laboratory before booking.

SampleBlood sample (EDTA tube), extracted DNA, or dried blood spot on FTA card.

MethodologyNext Generation Sequencing (NGS) targeting the RAG2 gene.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test analyzes specific regions of the RAG2 gene. It may not detect all possible mutations, such as deep intronic mutations or large deletions/duplications not detectable by NGS. Results must be interpreted in the context of clinical findings and family history. Confirm with the laboratory before booking.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

The RAG2 gene provides instructions for making a protein essential for the development of immune cells called T cells and B cells. Mutations in this gene can lead to immune deficiencies.

These are conditions where both T-cell (cellular) and B-cell (humoral) arms of the immune system are impaired, leading to increased susceptibility to infections.

Granulomas are small areas of inflammation that can form in various organs when the immune system tries to wall off substances it perceives as foreign but is unable to eliminate.

Discuss this test with your doctor, particularly if you have a history of recurrent infections, a family history of immune disorders, or unexplained granulomas.

This test focuses specifically on the RAG2 gene. Other genetic and non-genetic factors can affect the immune system. A comprehensive evaluation by a healthcare professional is necessary.

Genetic counseling is recommended to help understand the test results and their implications for you and your family. Please inquire about counseling services when booking.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp